Researchers at the Yale School of Medicine have identified a chemical inhibitor that limits the growth of lung tumor cells. The inhibitor works by partially disrupting glycosylation, the addition of sugar chains to proteins.
In a recent study, senior author and Yale pathology professor Wang Min demonstrated that the tumors release substances called cytokines to attract macrophages.
Cancer Moonshot Task Force Executive Director Greg Simon will speak at the 2016 AACI/CCAF Annual Meeting on Tuesday, October 25, in Chicago.
Searching for more individual genes to predict responses to breast cancer therapy may not work, a new study suggests. Instead, scientists and clinicians need to pay attention to abnormalities in networks of genes, Yale researchers report in a paper published Oct. 20 in the journal Annals of Oncology.
Fred Hutchinson Cancer Research Center today announced the appointment of Dr. Bruce Clurman to serve as its executive vice president and deputy director, effective Nov. 1.
When Memorial Sloan Kettering opened its doors along Commack Road in 2002, eastern Long Islanders no longer needed to navigate congested roadways and train lines bound for Manhattan to receive personalized cancer care. Today, more than 14 years later, MSK is reinforcing its commitment to the local community in the form of a 38,000-plus-square-foot addition complete with enhancements to both clinical programs and physical spaces.
The 2016 joint annual meeting of the Association of American Cancer Institutes (AACI) and the Cancer Center Administrators Forum (CCAF), October 23-25, in Chicago, will feature three panel discussions focused on precision medicine, and an update on AACI’s Academic Difference Initiative.
Worsening depression symptoms are associated with shorter survival for lung cancer patients, particularly those in the early stages of disease, according to a new U.S. study.
A Ludwig Cancer Research study has identified a metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma (GBM) and shown how it can potentially be exploited for therapy.
Currently, human papillomavirus (HPV) vaccination rates remain low across the U.S., with fewer than 40% of girls and just over 21% of boys receiving the recommended vaccine series. Research from Roswell Park Cancer Institute has identified barriers that need to be overcome to improve vaccination rates, as well as possible strategies for doing so. The study has been published online ahead of print in the Journal of Cancer Education.
Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network’s Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, today published new findings that challenge current beliefs about how and why pancreatic cancer is so aggressive.
To develop new approaches to cancer prevention, scientists have attempted to grow tumor cells from precursor states in animal models.
The University of Texas MD Anderson Cancer Center and the Houston Independent School District (HISD) have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students.
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
Fred Hutchinson Cancer Research Center today announced that Dr. Nancy E. Davidson, director of the University of Pittsburgh Cancer Institute, has accepted the position of executive director of clinical oncology for the Fred Hutch / University of Washington Cancer Consortium, one of 47 National Cancer Institute-designated Comprehensive Cancer Centers nationwide. Her appointment will become effective Dec. 1.
In a phase I clinical trial, patients with previously treated advanced non-small cell lung cancer (NSCLC) have showed initial response and disease control from the drug combination of ramucirumab and pembrolizumab. Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, will present the interim data of the clinical trial at the European Society for Medical Oncology (ESMO) Congress today.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of post-menopausal women with hormone receptor-positive metastatic breast cancer, compared to the hormone therapy alone.
African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center. The study, senior authored by Willie Underwood, III, MD, MPH, MSci, of Roswell Park, has been published online ahead of print in the journal Urology.
Clarivate Analytics announced its third place win with Georgetown University in the USPTO Cancer Moonshot Challenge held by the U.S. Commerce Department’s United States Patent and Trademark Office.
After an extensive national search, Smilow Cancer Hospital and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new YCC director and physician-in-chief at Smilow Cancer Hospital, effective Jan. 1, 2017.
The European Bioinformatics Institute (EMBL-EBI), the New York University School of Medicine and the Ontario Institute for Cancer Research (OICR) today announced a major milestone in the Reactome project: the annotation and release of its 10,000th human protein, making it the most comprehensive open access pathway knowledgebase available to the scientific community.
Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of the 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.
The Association of American Cancer Institutes will present the AACI Distinguished Scientist Award to James P. Allison, PhD, on October 24, during the 2016 AACI/CCAF Annual Meeting, in Chicago.
All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of Texas MD Anderson Cancer Center.
Today the Pancreatic Cancer Action Network announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer by tailoring their treatment to their cancer’s unique molecular profile. Fred Hutchinson Cancer Research Center will play a major role in the effort; it has been selected to lead one of the 12 initial clinical trial sites equipped to provide treatment to pancreatic cancer patients under the new initiative. Dr. Sunil Hingorani, an oncologist and pancreas cancer researcher based at Fred Hutch, will serve as principal investigator of the site and lead collaboration with clinical care partners Seattle Cancer Care Alliance and UW Medicine.
BUFFALO, N.Y. — What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a study based on 10 years of prospectively collected data on robot-assisted cystectomies, or surgeries to remove the bladder. The researchers, who shared their findings in a recent issue of the journal Urology, report that centers that carefully track various aspects of care can better predict patient outcomes and improve patient care.
The Turquoise Trail Harley Owner’s Group will end its second annual “Pink Your Ride — Motorcyclists Increasing Awareness (MIA)” ride at The University of New Mexico Comprehensive Cancer Center. The Turquoise Trail Chapter chose to join the Pennsylvania Chapter ride because of the widespread impact breast cancer has in New Mexico and in the United States. They hope to encourage others to join the ride here and elsewhere in the country.
NCCN has published new patient education materials for Stomach Cancer; these resources are available to download free of charge at NCCN.org/patients.
Award-winning ESPN journalist Chris Mortensen has been named this year’s NFL Players Association Georgetown Lombardi Award honoree.
A Yale-led research team has identified a new blocking mechanism that acts like a dimmer switch and inhibits lung tumor cell growth.
The UCSF Helen Diller Family Comprehensive Cancer Center is one of only 12 academic centers in the U.S. joining a large national precision medicine study that aims to improve survival for pancreatic cancer patients. The trial, called Precision Promise, is a joint effort between the Pancreatic Cancer Action Network, cancer research and treatment centers, and the pharmaceutical industry. The goal of Precision Promise is to double survival by 2020.
SEATTLE – (Sept. 20, 2016) – Seattle Cancer Care Alliance (SCCA) has opened a new Prostate Cancer Genetics Clinic at their South Lake Union campus in Seattle. The specialty clinic will serve patients with prostate cancer that has spread beyond the prostate (metastatic) and/or who have a family history of the disease or a family history of breast cancer, ovarian cancer, pancreatic cancer, lymphoma or leukemia. These men are more likely to have an inherited and more aggressive form of prostate cancer. Knowing a patient has a particular genetic mutation helps doctors choose the best treatment plan and can open doors for innovative clinical trials.
A $250,000 grant from the Breast Cancer Research Foundation awarded to a Rutgers Cancer Institute of New Jersey researcher will help further elucidate the inner workings of the p53 gene. The work will examine a drug compound that restores tumor suppressor function, with an aim of providing a foundation for the development of a new type of anti-cancer drug.
In animal models of human breast cancer, inhibiting a single protein restores sensitivity to tamoxifen, a commonly used drug for treatment of some breast cancers.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center, and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery. Reported by an international team of researchers and set to publish online in Cell on September 29, this work both defines a critical lesion that leads to lymphoma development and identifies a potential new treatment modality.
New research published Sept 29, 2016, in JAMA Oncology shows the HPV vaccine is efficacious in reducing cervical pre-cancers among young women throughout a population. The New Mexico HPV Pap Registry was the data source used in the study. The researchers found that among women who were 15 to 19 years old at the time of a diagnostic cervical biopsy, the incidence rate of cervical abnormalities decreased between 2007 and 2014.
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
The NCCN 11th Annual Congress: Hematologic Malignancies™ returns to New York City September 30 – October 1, 2016; registration is still open at NCCN.org/HEM
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer. Now, the ultrasmall particles have shown they can do something even better: kill cancer cells without attaching a cytotoxic drug.
In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
Currently, excess body weight contributes to as many as 1 in 5 cancer-related deaths. Obesity is associated with increased risk of at least eight types of cancer. The American Society of Clinical Oncology has identified obesity as a health risk that is “quickly overtaking tobacco as the leading preventable cause of cancer.”
Seattle Cancer Care Alliance (SCCA) has opened a new Prostate Cancer Genetics Clinic at their South Lake Union campus in Seattle. The specialty clinic will serve patients with prostate cancer that has spread beyond the prostate (metastatic) and/or who have a family history of the disease or a family history of breast cancer, ovarian cancer, pancreatic cancer, lymphoma or leukemia. These men are more likely to have an inherited and more aggressive form of prostate cancer. Knowing a patient has a particular genetic mutation helps doctors choose the best treatment plan and can open doors for innovative clinical trials.
A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right